PH12018502490A1 - Oral tipepidine preparation - Google Patents

Oral tipepidine preparation

Info

Publication number
PH12018502490A1
PH12018502490A1 PH12018502490A PH12018502490A PH12018502490A1 PH 12018502490 A1 PH12018502490 A1 PH 12018502490A1 PH 12018502490 A PH12018502490 A PH 12018502490A PH 12018502490 A PH12018502490 A PH 12018502490A PH 12018502490 A1 PH12018502490 A1 PH 12018502490A1
Authority
PH
Philippines
Prior art keywords
tipepidine
oral
preparation
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PH12018502490A
Inventor
Naomi Esaki
Kyoko Kawada
Kazuki Morizaki
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PH12018502490A1 publication Critical patent/PH12018502490A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides a novel oral composition of a single or twice daily dose type, which contains tipepidine or a pharmaceutically acceptable salt thereof, wherein the drug dissolution rate of tipepidine or the pharmaceutically acceptable salt thereof is controlled.
PH12018502490A 2016-05-30 2018-11-26 Oral tipepidine preparation PH12018502490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016107387 2016-05-30
PCT/JP2017/020038 WO2017209106A1 (en) 2016-05-30 2017-05-30 Oral tipepidine preparation

Publications (1)

Publication Number Publication Date
PH12018502490A1 true PH12018502490A1 (en) 2019-09-30

Family

ID=60478572

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502490A PH12018502490A1 (en) 2016-05-30 2018-11-26 Oral tipepidine preparation

Country Status (6)

Country Link
JP (1) JP6380922B2 (en)
KR (1) KR20180137566A (en)
PH (1) PH12018502490A1 (en)
SG (1) SG11201810308TA (en)
TW (1) TW201803564A (en)
WO (1) WO2017209106A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0759521B2 (en) * 1985-09-30 1995-06-28 藤沢薬品工業株式会社 Gel layer-forming sustained-release preparation
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JPH05255125A (en) * 1992-02-29 1993-10-05 Upjohn Co:The Sustained release preparation and its preparation
JPH1017497A (en) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd Sustained release pharmaceutical preparation and its production
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
JP5850299B2 (en) * 2010-04-28 2016-02-03 国立大学法人 熊本大学 Obsessive-compulsive disorder treatment
JP6032561B2 (en) * 2011-03-03 2016-11-30 国立大学法人 熊本大学 Drugs that improve central function in pain
JP5858477B2 (en) * 2011-09-01 2016-02-10 国立大学法人 熊本大学 Drugs for negative symptoms of schizophrenia
BR112015010663B1 (en) * 2012-11-15 2022-12-06 Incyte Holdings Corporation SUSTAINED RELEASE ORAL DOSAGE FORMS AND USE OF RUXOLITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Also Published As

Publication number Publication date
KR20180137566A (en) 2018-12-27
WO2017209106A1 (en) 2017-12-07
JP6380922B2 (en) 2018-08-29
JPWO2017209106A1 (en) 2018-07-19
TW201803564A (en) 2018-02-01
SG11201810308TA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2020002271A (en) Pharmaceutical compositions comprising sepiapterin and uses thereof.
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
MX2017016802A (en) Pharmaceutical formulations.
MX2019014292A (en) 5-5 FUSED RINGS AS C5a INHIBITORS.
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2017003561A (en) Compositions and methods for cannabinoid coatings for use in drug delivery.
MX2017013950A (en) Zolmitriptan powders for pulmonary delivery.
MX2019011639A (en) Pharmaceutical formulation.
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
PH12018502490A1 (en) Oral tipepidine preparation
PH12020500120A1 (en) Pharmaceutical compositions
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2020000144A (en) Pharmaceutical composition for nasal administration.
PH12016502527B1 (en) Stabilized desmopressin
PH12019501967A1 (en) Granules containing besifovir dipivoxil or pharmaceutically acceptable salt thereof, pharmaceutical composition comprising granules, and preparation method therefor
MX2018007272A (en) Pulsatile release pharmaceutical composition comprising naftazone or one of its salts.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
JOP20170198A1 (en) Pharmaceutical formulations comprising tenofovir and emtricitabine
MX2014008984A (en) Obtention process and pharmaceutical composition of capsules of fenofibrate as a lipid regulator of oral administration.